• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

    10/11/22 10:06:25 AM ET
    $ABC
    $ACMR
    $ADI
    $AMGN
    Other Pharmaceuticals
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ABC alert in real time by email

    Upgrades

    According to Deutsche Bank, the prior rating for Scorpio Tankers Inc (NYSE:STNG) was changed from Sell to Hold. For the second quarter, Scorpio Tankers had an EPS of $3.13, compared to year-ago quarter EPS of $0.94. The stock has a 52-week-high of $46.30 and a 52-week-low of $11.02. At the end of the last trading period, Scorpio Tankers closed at $40.74.

    Credit Suisse upgraded the previous rating for Algonquin Power & Utilities Corp (NYSE:AQN) from Neutral to Outperform. For the second quarter, Algonquin Power had an EPS of $0.16, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $16.01 and a 52-week-low of $10.38. At the end of the last trading period, Algonquin Power closed at $10.48.

    For AmerisourceBergen Corp (NYSE:ABC), B of A Securities upgraded the previous rating of Neutral to Buy. AmerisourceBergen earned $2.62 in the third quarter, compared to $2.16 in the year-ago quarter. The current stock performance of AmerisourceBergen shows a 52-week-high of $167.19 and a 52-week-low of $127.94. Moreover, at the end of the last trading period, the closing price was at $137.62.

    According to Morgan Stanley, the prior rating for Amgen Inc (NASDAQ:AMGN) was changed from Equal-Weight to Overweight. For the second quarter, Amgen had an EPS of $4.65, compared to year-ago quarter EPS of $4.38. At the moment, the stock has a 52-week-high of $258.45 and a 52-week-low of $214.39. Amgen closed at $232.15 at the end of the last trading period.

    Benchmark upgraded the previous rating for Getty Images Holdings Inc (NYSE:GETY) from Hold to Buy. Getty Images Holdings earned $0.29 in the second quarter, compared to $0.07 in the year-ago quarter. The current stock performance of Getty Images Holdings shows a 52-week-high of $37.88 and a 52-week-low of $5.75. Moreover, at the end of the last trading period, the closing price was at $6.27.

    For Seagen Inc (NASDAQ:SGEN), BMO Capital upgraded the previous rating of Market Perform to Outperform. In the second quarter, Seagen showed an EPS of $0.73, compared to $0.47 from the year-ago quarter. The current stock performance of Seagen shows a 52-week-high of $183.00 and a 52-week-low of $105.43. Moreover, at the end of the last trading period, the closing price was at $130.95.

    For Lululemon Athletica Inc (NASDAQ:LULU), Piper Sandler upgraded the previous rating of Neutral to Overweight. Lululemon Athletica earned $2.20 in the second quarter, compared to $1.65 in the year-ago quarter. The current stock performance of Lululemon Athletica shows a 52-week-high of $410.70 and a 52-week-low of $251.51. Moreover, at the end of the last trading period, the closing price was at $289.85.

    According to Piper Sandler, the prior rating for e.l.f. Beauty Inc (NYSE:ELF) was changed from Neutral to Overweight. For the first quarter, e.l.f. Beauty had an EPS of $0.39, compared to year-ago quarter EPS of $0.27. The stock has a 52-week-high of $41.31 and a 52-week-low of $20.49. At the end of the last trading period, e.l.f. Beauty closed at $37.49.

    Wells Fargo upgraded the previous rating for Marvell Technology Inc (NASDAQ:MRVL) from Equal-Weight to Overweight. For the second quarter, Marvell Tech had an EPS of $0.57, compared to year-ago quarter EPS of $0.34. The current stock performance of Marvell Tech shows a 52-week-high of $91.78 and a 52-week-low of $39.20. Moreover, at the end of the last trading period, the closing price was at $40.30.

    According to SVB Leerink, the prior rating for scPharmaceuticals Inc (NASDAQ:SCPH) was changed from Market Perform to Outperform. scPharmaceuticals earned $0.35 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.80 and a 52-week-low of $3.68. scPharmaceuticals closed at $4.02 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    According to UBS, the prior rating for BlackRock Inc (NYSE:BLK) was changed from Buy to Neutral. BlackRock earned $7.36 in the second quarter, compared to $10.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $927.48 and a 52-week-low of $541.33. BlackRock closed at $545.54 at the end of the last trading period.

    For ACM Research Inc (NASDAQ:ACMR), Jefferies downgraded the previous rating of Buy to Underperform. ACM Research earned $0.22 in the second quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $91.59 and a 52-week-low of $8.54. At the end of the last trading period, ACM Research closed at $9.04.

    According to Scotiabank, the prior rating for Mechel PAO (NYSE:MTL) was changed from Sector Outperform to Sector Perform. NoneThe stock has a 52-week-high of $4.32 and a 52-week-low of $1.88. At the end of the last trading period, Mechel PAO closed at $2.25.

    For Vitru Ltd (NASDAQ:VTRU), Goldman Sachs downgraded the previous rating of Buy to Neutral. Vitru earned $0.47 in the second quarter, compared to $0.18 in the year-ago quarter.

    Credit Suisse downgraded the previous rating for Cogent Communications Holdings Inc (NASDAQ:CCOI) from Outperform to Neutral. Cogent Comms Hldgs earned $0.24 in the second quarter, compared to $0.20 in the year-ago quarter. At the moment, the stock has a 52-week-high of $74.08 and a 52-week-low of $49.02. Cogent Comms Hldgs closed at $51.53 at the end of the last trading period.

    According to B of A Securities, the prior rating for SunPower Corp (NASDAQ:SPWR) was changed from Neutral to Underperform. SunPower earned $0.03 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $28.42 and a 52-week-low of $12.78. SunPower closed at $21.47 at the end of the last trading period.

    For Zoom Video Communications Inc (NASDAQ:ZM), Morgan Stanley downgraded the previous rating of Overweight to Equal-Weight. Zoom Video Comms earned $1.05 in the second quarter, compared to $1.36 in the year-ago quarter. The current stock performance of Zoom Video Comms shows a 52-week-high of $184.91 and a 52-week-low of $71.69. Moreover, at the end of the last trading period, the closing price was at $73.72.

    For Meta Platforms Inc (NASDAQ:META), Atlantic Equities downgraded the previous rating of Overweight to Neutral. In the second quarter, Meta Platforms showed an EPS of $2.46, compared to $3.61 from the year-ago quarter. The current stock performance of Meta Platforms shows a 52-week-high of $199.45 and a 52-week-low of $11.73. Moreover, at the end of the last trading period, the closing price was at $133.79.

    According to Wells Fargo, the prior rating for Skyworks Solutions Inc (NASDAQ:SWKS) was changed from Overweight to Equal-Weight. In the third quarter, Skyworks Solutions showed an EPS of $2.44, compared to $2.15 from the year-ago quarter. The current stock performance of Skyworks Solutions shows a 52-week-high of $163.47 and a 52-week-low of $83.28. Moreover, at the end of the last trading period, the closing price was at $83.92.

    Wells Fargo downgraded the previous rating for Qorvo Inc (NASDAQ:QRVO) from Overweight to Equal-Weight. For the first quarter, Qorvo had an EPS of $2.25, compared to year-ago quarter EPS of $2.83. The current stock performance of Qorvo shows a 52-week-high of $163.12 and a 52-week-low of $79.36. Moreover, at the end of the last trading period, the closing price was at $81.96.

    See all analyst ratings downgrades.

    Initiations

    With a Equal-Weight rating, Morgan Stanley initiated coverage on Nurix Therapeutics Inc (NASDAQ:NRIX). The price target seems to have been set at $11.00 for Nurix Therapeutics. For the third quarter, Nurix Therapeutics had an EPS of $0.90, compared to year-ago quarter EPS of $0.65. The current stock performance of Nurix Therapeutics shows a 52-week-high of $30.52 and a 52-week-low of $7.52. Moreover, at the end of the last trading period, the closing price was at $10.99.

    JP Morgan initiated coverage on CompoSecure Inc (NASDAQ:CMPO) with an Overweight rating. The price target for CompoSecure is set to $10.00. The stock has a 52-week-high of $9.09 and a 52-week-low of $4.72. At the end of the last trading period, CompoSecure closed at $5.26.

    With a Buy rating, Canaccord Genuity initiated coverage on Rapid7 Inc (NASDAQ:RPD). The price target seems to have been set at $60.00 for Rapid7. For the second quarter, Rapid7 had an EPS of $0.01, compared to year-ago quarter EPS of $0.07. The stock has a 52-week-high of $118.42 and a 52-week-low of $39.67. At the end of the last trading period, Rapid7 closed at $39.89.

    With a Buy rating, Canaccord Genuity initiated coverage on Qualys Inc (NASDAQ:QLYS). The price target seems to have been set at $180.00 for Qualys. For the second quarter, Qualys had an EPS of $0.89, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $162.36 and a 52-week-low of $108.10. Qualys closed at $131.12 at the end of the last trading period.

    With a Buy rating, Maxim Group initiated coverage on Xperi Inc (NYSE:XPER). The price target seems to have been set at $23.00 for Xperi. Xperi earned $0.52 in the second quarter, compared to $0.61 in the year-ago quarter. The stock has a 52-week-high of $19.90 and a 52-week-low of $13.30. At the end of the last trading period, Xperi closed at $13.74.

    Wedbush initiated coverage on Brown-Forman Corp (NYSE:BF) with a Neutral rating. The price target for Brown-Forman is set to $70.00.

    With a Neutral rating, Mizuho initiated coverage on Eastman Chemical Co (NYSE:EMN). The price target seems to have been set at $91.00 for Eastman Chemical. In the second quarter, Eastman Chemical showed an EPS of $2.83, compared to $2.46 from the year-ago quarter. The current stock performance of Eastman Chemical shows a 52-week-high of $129.47 and a 52-week-low of $69.91. Moreover, at the end of the last trading period, the closing price was at $71.78.

    With a Buy rating, Goldman Sachs initiated coverage on Enovis Corp (NYSE:ENOV). The price target seems to have been set at $57.00 for Enovis. For the second quarter, Enovis had an EPS of $0.59, compared to year-ago quarter EPS of $1.68. The stock has a 52-week-high of $72.13 and a 52-week-low of $44.77. At the end of the last trading period, Enovis closed at $44.86.

    With a Market Perform rating, Cowen & Co. initiated coverage on Texas Instruments Inc (NASDAQ:TXN). The price target seems to have been set at $170.00 for Texas Instruments. Texas Instruments earned $2.45 in the second quarter, compared to $2.05 in the year-ago quarter. The stock has a 52-week-high of $192.10 and a 52-week-low of $144.46. At the end of the last trading period, Texas Instruments closed at $156.79.

    Cowen & Co. initiated coverage on Analog Devices Inc (NASDAQ:ADI) with an Outperform rating. The price target for Analog Devices is set to $180.00. For the third quarter, Analog Devices had an EPS of $2.52, compared to year-ago quarter EPS of $1.72. At the moment, the stock has a 52-week-high of $180.01 and a 52-week-low of $138.50. Analog Devices closed at $140.90 at the end of the last trading period.

    With an Overweight rating, Morgan Stanley initiated coverage on Intellia Therapeutics Inc (NASDAQ:NTLA). The price target seems to have been set at $84.00 for Intellia Therapeutics. Intellia Therapeutics earned $1.33 in the second quarter, compared to $1.01 in the year-ago quarter. The current stock performance of Intellia Therapeutics shows a 52-week-high of $119.65 and a 52-week-low of $37.08. Moreover, at the end of the last trading period, the closing price was at $54.31.

    Morgan Stanley initiated coverage on United Therapeutics Corp (NASDAQ:UTHR) with an Overweight rating. The price target for United Therapeutics is set to $288.00. In the second quarter, United Therapeutics showed an EPS of $2.41, compared to $3.65 from the year-ago quarter. The stock has a 52-week-high of $245.48 and a 52-week-low of $158.38. At the end of the last trading period, United Therapeutics closed at $205.95.

    Morgan Stanley initiated coverage on Arcus Biosciences Inc (NYSE:RCUS) with an Overweight rating. The price target for Arcus Biosciences is set to $40.00. Arcus Biosciences earned $0.93 in the second quarter, compared to $1.09 in the year-ago quarter. The stock has a 52-week-high of $42.05 and a 52-week-low of $16.74. At the end of the last trading period, Arcus Biosciences closed at $26.15.

    With an Underweight rating, Morgan Stanley initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP). The price target seems to have been set at $37.00 for CRISPR Therapeutics. For the second quarter, CRISPR Therapeutics had an EPS of $2.40, compared to year-ago quarter EPS of $9.44. The stock has a 52-week-high of $86.95 and a 52-week-low of $42.51. At the end of the last trading period, CRISPR Therapeutics closed at $60.82.

    Morgan Stanley initiated coverage on C4 Therapeutics Inc (NASDAQ:CCCC) with an Underweight rating. The price target for C4 Therapeutics is set to $6.00. For the second quarter, C4 Therapeutics had an EPS of $0.56, compared to year-ago quarter EPS of $0.51. The stock has a 52-week-high of $33.76 and a 52-week-low of $4.84. At the end of the last trading period, C4 Therapeutics closed at $7.73.

    Morgan Stanley initiated coverage on Revance Therapeutics Inc (NASDAQ:RVNC) with a Equal-Weight rating. The price target for Revance Therapeutics is set to $27.00. Revance Therapeutics earned $0.88 in the second quarter, compared to $1.07 in the year-ago quarter. The stock has a 52-week-high of $30.95 and a 52-week-low of $11.27. At the end of the last trading period, Revance Therapeutics closed at $28.89.

    UBS initiated coverage on Rani Therapeutics Holdings Inc (NASDAQ:RANI) with a Buy rating. The price target for Rani Therapeutics Hldgs is set to $15.00. For the second quarter, Rani Therapeutics Hldgs had an EPS of $0.31, compared to year-ago quarter EPS of $0.12. The current stock performance of Rani Therapeutics Hldgs shows a 52-week-high of $27.13 and a 52-week-low of $6.73. Moreover, at the end of the last trading period, the closing price was at $7.00.

    UBS initiated coverage on Neurocrine Biosciences Inc (NASDAQ:NBIX) with a Buy rating. The price target for Neurocrine Biosciences is set to $136.00. In the second quarter, Neurocrine Biosciences showed an EPS of $0.84, compared to $0.63 from the year-ago quarter. The current stock performance of Neurocrine Biosciences shows a 52-week-high of $113.63 and a 52-week-low of $71.88. Moreover, at the end of the last trading period, the closing price was at $106.84.

    UBS initiated coverage on Cytokinetics Inc (NASDAQ:CYTK) with a Buy rating. The price target for Cytokinetics is set to $80.00. For the second quarter, Cytokinetics had an EPS of $0.23, compared to year-ago quarter EPS of $0.86. The current stock performance of Cytokinetics shows a 52-week-high of $55.80 and a 52-week-low of $29.26. Moreover, at the end of the last trading period, the closing price was at $47.23.

    With an Underweight rating, Barclays initiated coverage on Roblox Corp (NYSE:RBLX). The price target seems to have been set at $20.00 for Roblox. In the second quarter, Roblox showed an EPS of $0.30, compared to $0.25 from the year-ago quarter. At the moment, the stock has a 52-week-high of $103.79 and a 52-week-low of $21.65. Roblox closed at $35.40 at the end of the last trading period.

    With a Neutral rating, Citigroup initiated coverage on Corebridge Financial Inc (NYSE:CRBG). The price target seems to have been set at $23.00 for Corebridge Financial. The stock has a 52-week-high of $22.00 and a 52-week-low of $19.14. At the end of the last trading period, Corebridge Financial closed at $19.69.

    Wells Fargo initiated coverage on Elastic NV (NYSE:ESTC) with an Underweight rating. The price target for Elastic is set to $73.00. Elastic earned $0.15 in the first quarter, compared to $0.04 in the year-ago quarter. The current stock performance of Elastic shows a 52-week-high of $124.25 and a 52-week-low of $50.74. Moreover, at the end of the last trading period, the closing price was at $66.78.

    Bernstein initiated coverage on Snowflake Inc (NYSE:SNOW) with a Market Perform rating. Snowflake earned $0.01 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $344.00 and a 52-week-low of $110.27. Snowflake closed at $159.05 at the end of the last trading period.

    Wells Fargo initiated coverage on Splunk Inc (NASDAQ:SPLK) with an Overweight rating. The price target for Splunk is set to $95.00. Splunk earned $0.09 in the second quarter, compared to $0.62 in the year-ago quarter. The current stock performance of Splunk shows a 52-week-high of $150.79 and a 52-week-low of $71.11. Moreover, at the end of the last trading period, the closing price was at $72.12.

    With an Overweight rating, Wells Fargo initiated coverage on Datadog Inc (NASDAQ:DDOG). The price target seems to have been set at $120.00 for Datadog. Datadog earned $0.24 in the second quarter, compared to $0.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $184.70 and a 52-week-low of $81.12. Datadog closed at $84.02 at the end of the last trading period.

    With an Overweight rating, Wells Fargo initiated coverage on Dynatrace Inc (NYSE:DT). The price target seems to have been set at $45.00 for Dynatrace. Dynatrace earned $0.18 in the first quarter, compared to $0.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.17 and a 52-week-low of $29.41. Dynatrace closed at $34.69 at the end of the last trading period.

    With a Buy rating, Deutsche Bank initiated coverage on International Seaways Inc (NYSE:INSW). The price target seems to have been set at $40.00 for International Seaways. International Seaways earned $1.43 in the second quarter, compared to $0.51 in the year-ago quarter. The current stock performance of International Seaways shows a 52-week-high of $36.72 and a 52-week-low of $13.05. Moreover, at the end of the last trading period, the closing price was at $34.31.

    With a Buy rating, Goldman Sachs initiated coverage on Warner Music Group Corp (NASDAQ:WMG). The price target seems to have been set at $32.00 for Warner Music Group. For the third quarter, Warner Music Group had an EPS of $0.28, compared to year-ago quarter EPS of $0.16. At the moment, the stock has a 52-week-high of $44.64 and a 52-week-low of $22.08. Warner Music Group closed at $22.35 at the end of the last trading period.

    Mizuho initiated coverage on Celanese Corp (NYSE:CE) with a Neutral rating. The price target for Celanese is set to $116.00. Celanese earned $4.99 in the second quarter, compared to $5.02 in the year-ago quarter. The current stock performance of Celanese shows a 52-week-high of $176.50 and a 52-week-low of $86.70. Moreover, at the end of the last trading period, the closing price was at $91.85.

    Oppenheimer initiated coverage on POINT Biopharma Global Inc (NASDAQ:PNT) with an Outperform rating. The price target for POINT Biopharma Global is set to $20.00. For the second quarter, POINT Biopharma Global had an EPS of $0.27, compared to year-ago quarter EPS of $0.15. The current stock performance of POINT Biopharma Global shows a 52-week-high of $10.98 and a 52-week-low of $5.22. Moreover, at the end of the last trading period, the closing price was at $7.28.

    With an Outperform rating, Wedbush initiated coverage on Keurig Dr Pepper Inc (NASDAQ:KDP). The price target seems to have been set at $43.00 for Keurig Dr Pepper. In the second quarter, Keurig Dr Pepper showed an EPS of $0.39, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $41.31 and a 52-week-low of $33.35. At the end of the last trading period, Keurig Dr Pepper closed at $36.97.

    With a Neutral rating, Wedbush initiated coverage on Monster Beverage Corp (NASDAQ:MNST). The price target seems to have been set at $95.00 for Monster Beverage. Monster Beverage earned $0.51 in the second quarter, compared to $0.75 in the year-ago quarter. The stock has a 52-week-high of $99.81 and a 52-week-low of $71.78. At the end of the last trading period, Monster Beverage closed at $91.02.

    With an Outperform rating, Wedbush initiated coverage on Coca-Cola Co (NYSE:KO). The price target seems to have been set at $63.00 for Coca-Cola. Coca-Cola earned $0.70 in the second quarter, compared to $0.68 in the year-ago quarter. At the moment, the stock has a 52-week-high of $67.20 and a 52-week-low of $54.02. Coca-Cola closed at $54.39 at the end of the last trading period.

    With a Neutral rating, Wedbush initiated coverage on Boston Beer Co Inc (NYSE:SAM). The price target seems to have been set at $350.00 for Boston Beer Co. Boston Beer Co earned $4.31 in the second quarter, compared to $4.75 in the year-ago quarter. The current stock performance of Boston Beer Co shows a 52-week-high of $535.00 and a 52-week-low of $287.00. Moreover, at the end of the last trading period, the closing price was at $348.25.

    Wedbush initiated coverage on The Duckhorn Portfolio Inc (NYSE:NAPA) with an Outperform rating. The price target for Duckhorn Portfolio is set to $18.00. Duckhorn Portfolio earned $0.08 in the fourth quarter, compared to $0.08 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.57 and a 52-week-low of $12.64. Duckhorn Portfolio closed at $14.43 at the end of the last trading period.

    With an Outperform rating, Wedbush initiated coverage on PepsiCo Inc (NASDAQ:PEP). The price target seems to have been set at $185.00 for PepsiCo. PepsiCo earned $1.86 in the second quarter, compared to $1.72 in the year-ago quarter. The stock has a 52-week-high of $181.07 and a 52-week-low of $153.37. At the end of the last trading period, PepsiCo closed at $161.82.

    With an Outperform rating, Wedbush initiated coverage on MGP Ingredients Inc (NASDAQ:MGPI). The price target seems to have been set at $125.00 for MGP Ingredients. For the second quarter, MGP Ingredients had an EPS of $1.15, compared to year-ago quarter EPS of $1.27. The stock has a 52-week-high of $117.01 and a 52-week-low of $73.02. At the end of the last trading period, MGP Ingredients closed at $105.04.

    Wedbush initiated coverage on Constellation Brands Inc (NYSE:STZ) with an Outperform rating. The price target for Constellation Brands is set to $275.00. Constellation Brands earned $3.17 in the second quarter, compared to $2.38 in the year-ago quarter. The current stock performance of Constellation Brands shows a 52-week-high of $261.52 and a 52-week-low of $207.59. Moreover, at the end of the last trading period, the closing price was at $221.24.

    With a Neutral rating, Wedbush initiated coverage on Molson Coors Beverage Co (NYSE:TAP). The price target seems to have been set at $50.00 for Molson Coors Beverage. In the second quarter, Molson Coors Beverage showed an EPS of $1.19, compared to $1.58 from the year-ago quarter. The stock has a 52-week-high of $60.12 and a 52-week-low of $46.47. At the end of the last trading period, Molson Coors Beverage closed at $47.31.

    Wedbush initiated coverage on Celsius Holdings Inc (NASDAQ:CELH) with a Neutral rating. The price target for Celsius Holdings is set to $90.00. In the second quarter, Celsius Holdings showed an EPS of $0.12, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $118.19 and a 52-week-low of $38.31. Celsius Holdings closed at $89.24 at the end of the last trading period.

    Wolfe Research initiated coverage on Virgin Galactic Holdings Inc (NYSE:SPCE) with an Underperform rating. The price target for Virgin Galactic Hldgs is set to $4.00. In the second quarter, Virgin Galactic Hldgs showed an EPS of $0.43, compared to $0.39 from the year-ago quarter. At the moment, the stock has a 52-week-high of $13.73 and a 52-week-low of $4.68. Virgin Galactic Hldgs closed at $4.92 at the end of the last trading period.

    With an Underperform rating, Wolfe Research initiated coverage on Spirit AeroSystems Holdings Inc (NYSE:SPR). The price target seems to have been set at $24.00 for Spirit AeroSystems Hldgs. Spirit AeroSystems Hldgs earned $1.21 in the second quarter, compared to $0.31 in the year-ago quarter. The current stock performance of Spirit AeroSystems Hldgs shows a 52-week-high of $53.31 and a 52-week-low of $21.51. Moreover, at the end of the last trading period, the closing price was at $24.95.

    With an Underperform rating, Wolfe Research initiated coverage on Triumph Group Inc (NYSE:TGI). The price target seems to have been set at $9.00 for Triumph Group. In the first quarter, Triumph Group showed an EPS of $0.12, compared to $0.09 from the year-ago quarter. At the moment, the stock has a 52-week-high of $27.85 and a 52-week-low of $8.58. Triumph Group closed at $8.93 at the end of the last trading period.

    Wolfe Research initiated coverage on Woodward Inc (NASDAQ:WWD) with an Outperform rating. The price target for Woodward is set to $100.00. Woodward earned $0.64 in the third quarter, compared to $0.74 in the year-ago quarter. The stock has a 52-week-high of $129.12 and a 52-week-low of $79.26. At the end of the last trading period, Woodward closed at $84.43.

    For Barnes Group Inc (NYSE:B), Wolfe Research initiated coverage, by setting the current rating at Peer Perform. For the second quarter, Barnes Gr had an EPS of $0.56, compared to year-ago quarter EPS of $0.45. The stock has a 52-week-high of $48.79 and a 52-week-low of $27.93. At the end of the last trading period, Barnes Gr closed at $32.06.

    Wolfe Research initiated coverage on TransDigm Group Inc (NYSE:TDG) with an Outperform rating. The price target for TransDigm Gr is set to $650.00. TransDigm Gr earned $4.85 in the third quarter, compared to $3.33 in the year-ago quarter. The stock has a 52-week-high of $684.72 and a 52-week-low of $500.08. At the end of the last trading period, TransDigm Gr closed at $531.52.

    Wolfe Research initiated coverage on Raytheon Technologies Corp (NYSE:RTX) with a Peer Perform rating. Raytheon Technologies earned $1.16 in the second quarter, compared to $1.03 in the year-ago quarter. The current stock performance of Raytheon Technologies shows a 52-week-high of $106.02 and a 52-week-low of $80.27. Moreover, at the end of the last trading period, the closing price was at $84.16.

    With an Outperform rating, Wolfe Research initiated coverage on Northrop Grumman Corp (NYSE:NOC). The price target seems to have been set at $565.00 for Northrop Grumman. Northrop Grumman earned $6.06 in the second quarter, compared to $6.42 in the year-ago quarter. The current stock performance of Northrop Grumman shows a 52-week-high of $515.49 and a 52-week-low of $364.62. Moreover, at the end of the last trading period, the closing price was at $503.83.

    Wolfe Research initiated coverage on Curtiss-Wright Corp (NYSE:CW) with an Outperform rating. The price target for Curtiss-Wright is set to $170.00. Curtiss-Wright earned $1.83 in the second quarter, compared to $1.56 in the year-ago quarter. The current stock performance of Curtiss-Wright shows a 52-week-high of $162.98 and a 52-week-low of $124.37. Moreover, at the end of the last trading period, the closing price was at $148.43.

    Wolfe Research initiated coverage on Lockheed Martin Corp (NYSE:LMT) with a Peer Perform rating. Lockheed Martin earned $6.32 in the second quarter, compared to $6.52 in the year-ago quarter. At the moment, the stock has a 52-week-high of $479.99 and a 52-week-low of $353.03. Lockheed Martin closed at $409.99 at the end of the last trading period.

    Wolfe Research initiated coverage on Embraer SA (NYSE:ERJ) with an Outperform rating. The price target for Embraer is set to $14.00. In the second quarter, Embraer showed an EPS of $0.21, compared to $0.24 from the year-ago quarter. At the moment, the stock has a 52-week-high of $18.08 and a 52-week-low of $7.91. Embraer closed at $9.55 at the end of the last trading period.

    Wolfe Research initiated coverage on L3Harris Technologies Inc (NYSE:LHX) with a Peer Perform rating. In the second quarter, L3Harris Technologies showed an EPS of $3.23, compared to $3.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $279.71 and a 52-week-low of $206.04. L3Harris Technologies closed at $230.44 at the end of the last trading period.

    With an Outperform rating, Wolfe Research initiated coverage on General Dynamics Corp (NYSE:GD). The price target seems to have been set at $265.00 for General Dynamics. General Dynamics earned $2.75 in the second quarter, compared to $2.61 in the year-ago quarter. The current stock performance of General Dynamics shows a 52-week-high of $254.99 and a 52-week-low of $200.65. Moreover, at the end of the last trading period, the closing price was at $225.41.

    For Hexcel Corp (NYSE:HXL), Wolfe Research initiated coverage, by setting the current rating at Peer Perform. In the second quarter, Hexcel showed an EPS of $0.33, compared to $0.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $65.82 and a 52-week-low of $47.38. Hexcel closed at $54.06 at the end of the last trading period.

    Wolfe Research initiated coverage on Heico Corp (NYSE:HEI) with a Peer Perform rating. In the third quarter, Heico showed an EPS of $0.60, compared to $0.56 from the year-ago quarter. The current stock performance of Heico shows a 52-week-high of $165.61 and a 52-week-low of $126.95. Moreover, at the end of the last trading period, the closing price was at $148.92.

    Wolfe Research initiated coverage on Huntington Ingalls Industries Inc (NYSE:HII) with an Outperform rating. The price target for Huntington Ingalls Indus is set to $315.00. For the second quarter, Huntington Ingalls Indus had an EPS of $4.44, compared to year-ago quarter EPS of $3.20. The stock has a 52-week-high of $243.46 and a 52-week-low of $177.20. At the end of the last trading period, Huntington Ingalls Indus closed at $235.06.

    Wolfe Research initiated coverage on Boeing Co (NYSE:BA) with an Outperform rating. The price target for Boeing is set to $180.00. In the second quarter, Boeing showed an EPS of $0.37, compared to $0.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $229.67 and a 52-week-low of $113.02. Boeing closed at $131.90 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ABC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABC
    $ACMR
    $ADI
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Monster Beverage Corporation
    $MNST
    2/27/2026$80.00 → $88.00Hold
    TD Cowen
    Monster Beverage Corporation
    $MNST
    2/27/2026$80.00 → $100.00Buy
    Jefferies
    Monster Beverage Corporation
    $MNST
    2/27/2026$88.00 → $94.00Buy
    Deutsche Bank
    Dynatrace Inc.
    $DT
    2/27/2026$36.00Neutral
    Macquarie
    Heico Corporation
    $HEI
    2/27/2026Neutral → Outperform
    BNP Paribas Exane
    Celsius Holdings Inc.
    $CELH
    2/27/2026$65.00Underperform → Buy
    BofA Securities
    Monster Beverage Corporation
    $MNST
    2/27/2026$82.00 → $92.00Buy
    Stifel
    Monster Beverage Corporation
    $MNST
    2/27/2026$90.00 → $100.00Buy
    Citigroup
    More analyst ratings

    $ABC
    $ACMR
    $ADI
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Secretary of War Pete Hegseth Visits L3Harris Solid Rocket Motor Site

    Secretary of War Pete Hegseth visited the L3Harris Technologies (NYSE:LHX) Camden site today as part of his nationwide "Arsenal of Freedom" tour, highlighting the importance of American manufacturing capacity in strengthening the defense industrial base and supporting U.S. and allied warfighters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227797011/en/Secretary of War Pete Hegseth addresses a crowd of approximately 1,500 L3Harris employees in Camden, Arkansas, as part of his "Arsenal of Freedom" tour. Secretary Hegseth toured several of the site's solid rocket motor production facilities and spoke with the 1,500 employees

    2/27/26 6:45:00 PM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

    STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 78,000 stock options of series 2019/2028. As of February 27, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,719,485 shares, of which 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of vo

    2/27/26 12:55:00 PM ET
    $B
    Precious Metals
    Basic Materials

    lululemon Responds to Chip Wilson's Statements

    lululemon athletica inc. (NASDAQ:LULU) ("lululemon" or the "company") today commented on Chip Wilson's press release in relation to his nomination of three director candidates to stand for election to the company's Board at lululemon's 2026 Annual Meeting of Shareholders: We have continued to engage with Mr. Wilson in good faith over the past few months, including numerous meetings, with the goal of having a productive dialogue with him. We disagree with Mr. Wilson's characterization of his interactions with the Board. The Board has repeatedly requested the opportunity to interview Mr. Wilson's director nominees. However, Mr. Wilson had indicated he would not allow the Board to meet wit

    2/27/26 11:39:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $ABC
    $ACMR
    $ADI
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President & Controller Oshodi Adewale exercised 1,551 shares at a strike of $21.58 and covered exercise/tax liability with 1,052 shares, increasing direct ownership by 5% to 10,077 units (SEC Form 4)

    4 - International Seaways, Inc. (0001679049) (Issuer)

    2/27/26 6:47:19 PM ET
    $INSW
    Marine Transportation
    Consumer Discretionary

    Director Alford Peggy sold $252,056 worth of shares (392 units at $643.00) (SEC Form 4)

    4 - Meta Platforms, Inc. (0001326801) (Issuer)

    2/27/26 6:36:18 PM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    Ex VP & Chief HR Officer Hughes Edmond E. Jr. was granted 4,782 shares and covered exercise/tax liability with 2,123 shares, increasing direct ownership by 29% to 11,723 units (SEC Form 4)

    4 - HUNTINGTON INGALLS INDUSTRIES, INC. (0001501585) (Issuer)

    2/27/26 4:19:09 PM ET
    $HII
    Marine Transportation
    Industrials

    $ABC
    $ACMR
    $ADI
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Small Robert J bought $1,285 worth of shares (1 units at $1,285.00) (SEC Form 4)

    4 - TransDigm Group INC (0001260221) (Issuer)

    2/27/26 4:22:59 PM ET
    $TDG
    Military/Government/Technical
    Industrials

    Director Farrell Matthew bought $464,814 worth of shares (5,000 units at $92.96), increasing direct ownership by 86% to 10,820 units (SEC Form 4)

    4 - e.l.f. Beauty, Inc. (0001600033) (Issuer)

    2/23/26 4:07:34 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Winnefeld James A Jr bought $4,901 worth of Class B Common Stock (100 units at $49.01), increasing direct ownership by 0.45% to 22,288 units (SEC Form 4)

    4 - MOLSON COORS BEVERAGE CO (0000024545) (Issuer)

    2/20/26 4:31:10 PM ET
    $TAP
    Beverages (Production/Distribution)
    Consumer Staples

    $ABC
    $ACMR
    $ADI
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on Monster Beverage with a new price target

    TD Cowen reiterated coverage of Monster Beverage with a rating of Hold and set a new price target of $88.00 from $80.00 previously

    2/27/26 12:43:30 PM ET
    $MNST
    Beverages (Production/Distribution)
    Consumer Staples

    Jefferies reiterated coverage on Monster Beverage with a new price target

    Jefferies reiterated coverage of Monster Beverage with a rating of Buy and set a new price target of $100.00 from $80.00 previously

    2/27/26 10:49:42 AM ET
    $MNST
    Beverages (Production/Distribution)
    Consumer Staples

    Deutsche Bank reiterated coverage on Monster Beverage with a new price target

    Deutsche Bank reiterated coverage of Monster Beverage with a rating of Buy and set a new price target of $94.00 from $88.00 previously

    2/27/26 9:35:15 AM ET
    $MNST
    Beverages (Production/Distribution)
    Consumer Staples

    $ABC
    $ACMR
    $ADI
    $AMGN
    SEC Filings

    View All

    SEC Form DEFA14A filed by lululemon athletica inc.

    DEFA14A - lululemon athletica inc. (0001397187) (Filer)

    2/27/26 5:19:59 PM ET
    $LULU
    Apparel
    Consumer Discretionary

    SEC Form 10-K filed by Zoom Communications Inc.

    10-K - Zoom Communications, Inc. (0001585521) (Filer)

    2/27/26 5:18:02 PM ET
    $ZM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 10-Q filed by Elastic N.V.

    10-Q - Elastic N.V. (0001707753) (Filer)

    2/27/26 4:08:28 PM ET
    $ESTC
    Computer Software: Prepackaged Software
    Technology

    $ABC
    $ACMR
    $ADI
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABC
    $ACMR
    $ADI
    $AMGN
    Financials

    Live finance-specific insights

    View All

    Monster Beverage Reports 2025 Fourth Quarter and Full-Year Financial Results

    2025 Fourth Quarter Highlights  Net Sales rise 17.6 percent to $2.13 billion Operating Income increases 42.3 percent to $542.6 million (16.0 percent to $617.6 million on a non-GAAP adjusted basis)1Net Income increases 65.9 percent to $449.2 million (31.2 percent to $507.0 million on a non-GAAP adjusted basis)Net Income Per Diluted Share increases 64.9 percent to $0.46 per share (30.4 percent to $0.51 per share on a non-GAAP adjusted basis) 1 The tables at the end of this press release provide a reconciliation of non-GAAP financial measures to the Company's results, as reported under GAAP. (See "Reconciliation of GAAP and Non-GAAP Information" below). CORONA, Calif., Feb. 26, 2026 (GLOBE

    2/26/26 4:10:00 PM ET
    $MNST
    Beverages (Production/Distribution)
    Consumer Staples

    Elastic Reports Third Quarter Fiscal 2026 Financial Results

    Q3 Revenue of $450 million, up 18% year-over-year Elastic (NYSE:ESTC), the Search AI Company, announced financial results for its third quarter of fiscal 2026 ended January 31, 2026. Third Quarter Fiscal 2026 Financial Highlights Total revenue was $450 million, an increase of 18% year-over-year, or 16% on a constant currency basis Total subscription revenue was $426 million, an increase of 19% year-over-year, or 17% on a constant currency basis Sales-led subscription revenue (calculated as subscription revenue excluding Monthly Elastic Cloud) was $376 million, an increase of 21% year-over-year, or 19% on a constant currency basis Current remaining performance obligations wer

    2/26/26 4:05:00 PM ET
    $ESTC
    Computer Software: Prepackaged Software
    Technology

    Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

    HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical com

    2/26/26 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABC
    $ACMR
    $ADI
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Chip Wilson Provides Update to lululemon Shareholders

    VANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Chip Wilson, Founder of lululemon athletica inc. (NASDAQ:LULU) ("lululemon" or the "Company") and one of lululemon's largest shareholders, today released the following letter to lululemon shareholders: Shareholders of lululemon:In support of all shareholders, I am pursuing a campaign to catalyze a quantum of change that is sorely needed at lululemon. To effect that change, I have pursued private, constructive dialogues with the lululemon Board of Directors (the "Board") for the past few months. My attempts toward a sensible solution have not been reciprocated.The heart of the issue is a disconnect between the Company's creative engine and the Board's str

    2/27/26 8:00:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    The Coca-Cola Company Announces Participation in Citi 2026 Global Consumer & Retail Conference

    The Coca-Cola Company announced today that John Murphy, President and Chief Financial Officer, will present at the Citi 2026 Global Consumer & Retail Conference March 9 at 8 a.m. ET. The company invites investors to join a webcast for this event at coca-colacompany.com/investors. Downloadable files, as well as a transcript, will be available within 24 hours after the event on the company's website. About The Coca-Cola Company The Coca-Cola Company (NYSE:KO) is a total beverage company with products sold in more than 200 countries and territories. Our company's purpose is to refresh the world and make a difference. We sell multiple billion-dollar brands across several beverage categori

    2/25/26 10:00:00 AM ET
    $KO
    Beverages (Production/Distribution)
    Consumer Staples

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    $ABC
    $ACMR
    $ADI
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CRISPR Therapeutics AG

    SC 13G/A - CRISPR Therapeutics AG (0001674416) (Subject)

    12/10/24 1:34:45 PM ET
    $CRSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BlackRock Inc.

    SC 13G/A - BlackRock, Inc. (0002012383) (Filed by)

    12/6/24 4:32:58 PM ET
    $BLK
    Investment Bankers/Brokers/Service
    Finance